Skip to main content
NASDAQ:SDGR

Schrödinger Competitors

$61.45
+0.21 (+0.34 %)
(As of 05/17/2021 12:00 AM ET)
Add
Compare
Today's Range
$59.00
$61.68
50-Day Range
$59.02
$78.57
52-Week Range
$46.27
$117.00
Volume547,644 shs
Average Volume1.04 million shs
Market Capitalization$4.30 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Schrödinger (NASDAQ:SDGR) Vs. ELAN, ALNY, ZLAB, BMRN, GRFS, and RDY

Should you be buying SDGR stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Schrödinger, including Elanco Animal Health (ELAN), Alnylam Pharmaceuticals (ALNY), Zai Lab (ZLAB), BioMarin Pharmaceutical (BMRN), Grifols (GRFS), and Dr. Reddy's Laboratories (RDY).

Schrödinger (NASDAQ:SDGR) and Elanco Animal Health (NYSE:ELAN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, earnings, dividends, analyst recommendations and institutional ownership.

Analyst Ratings

This is a breakdown of current recommendations for Schrödinger and Elanco Animal Health, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Schrödinger01302.75
Elanco Animal Health13902.62

Schrödinger presently has a consensus target price of $84.00, indicating a potential upside of 36.70%. Elanco Animal Health has a consensus target price of $33.1364, indicating a potential downside of 5.35%. Given Schrödinger's stronger consensus rating and higher probable upside, analysts clearly believe Schrödinger is more favorable than Elanco Animal Health.

Insider and Institutional Ownership

41.3% of Schrödinger shares are held by institutional investors. Comparatively, 86.8% of Elanco Animal Health shares are held by institutional investors. 0.1% of Elanco Animal Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Schrödinger and Elanco Animal Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Schrödinger-19.92%-7.25%-5.33%
Elanco Animal Health-8.45%3.43%2.04%

Earnings & Valuation

This table compares Schrödinger and Elanco Animal Health's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Schrödinger$85.54 million50.30$-24,570,000.00N/AN/A
Elanco Animal Health$3.07 billion5.39$67.90 million$1.0633.03

Elanco Animal Health has higher revenue and earnings than Schrödinger.

Summary

Elanco Animal Health beats Schrödinger on 8 of the 11 factors compared between the two stocks.

Schrödinger (NASDAQ:SDGR) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, earnings, dividends, analyst recommendations and institutional ownership.

Analyst Ratings

This is a breakdown of current recommendations for Schrödinger and Alnylam Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Schrödinger01302.75
Alnylam Pharmaceuticals08802.50

Schrödinger presently has a consensus target price of $84.00, indicating a potential upside of 36.70%. Alnylam Pharmaceuticals has a consensus target price of $168.7333, indicating a potential upside of 24.17%. Given Schrödinger's stronger consensus rating and higher probable upside, analysts clearly believe Schrödinger is more favorable than Alnylam Pharmaceuticals.

Insider and Institutional Ownership

41.3% of Schrödinger shares are held by institutional investors. Comparatively, 92.4% of Alnylam Pharmaceuticals shares are held by institutional investors. 3.5% of Alnylam Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Schrödinger and Alnylam Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Schrödinger-19.92%-7.25%-5.33%
Alnylam Pharmaceuticals-222.19%-65.96%-31.38%

Earnings & Valuation

This table compares Schrödinger and Alnylam Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Schrödinger$85.54 million50.30$-24,570,000.00N/AN/A
Alnylam Pharmaceuticals$219.75 million72.69$-886,120,000.00($8.11)-16.76

Schrödinger has higher earnings, but lower revenue than Alnylam Pharmaceuticals.

Summary

Schrödinger beats Alnylam Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

Schrödinger (NASDAQ:SDGR) and Zai Lab (NASDAQ:ZLAB) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, earnings, dividends, analyst recommendations and institutional ownership.

Analyst Ratings

This is a breakdown of current recommendations for Schrödinger and Zai Lab, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Schrödinger01302.75
Zai Lab00503.00

Schrödinger presently has a consensus target price of $84.00, indicating a potential upside of 36.70%. Zai Lab has a consensus target price of $197.8460, indicating a potential upside of 28.48%. Given Schrödinger's higher probable upside, analysts clearly believe Schrödinger is more favorable than Zai Lab.

Insider and Institutional Ownership

41.3% of Schrödinger shares are held by institutional investors. Comparatively, 81.3% of Zai Lab shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Schrödinger and Zai Lab's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Schrödinger-19.92%-7.25%-5.33%
Zai LabN/AN/AN/A

Earnings & Valuation

This table compares Schrödinger and Zai Lab's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Schrödinger$85.54 million50.30$-24,570,000.00N/AN/A
Zai Lab$12.98 million1,123.31$-195,070,000.00($3.03)-50.82

Schrödinger has higher revenue and earnings than Zai Lab.

Summary

Zai Lab beats Schrödinger on 7 of the 10 factors compared between the two stocks.

Schrödinger (NASDAQ:SDGR) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, earnings, dividends, analyst recommendations and institutional ownership.

Analyst Ratings

This is a breakdown of current recommendations for Schrödinger and BioMarin Pharmaceutical, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Schrödinger01302.75
BioMarin Pharmaceutical071002.59

Schrödinger presently has a consensus target price of $84.00, indicating a potential upside of 36.70%. BioMarin Pharmaceutical has a consensus target price of $118.20, indicating a potential upside of 52.83%. Given BioMarin Pharmaceutical's higher probable upside, analysts clearly believe BioMarin Pharmaceutical is more favorable than Schrödinger.

Insider and Institutional Ownership

41.3% of Schrödinger shares are held by institutional investors. Comparatively, 97.7% of BioMarin Pharmaceutical shares are held by institutional investors. 2.2% of BioMarin Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Schrödinger and BioMarin Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Schrödinger-19.92%-7.25%-5.33%
BioMarin Pharmaceutical45.74%4.34%2.84%

Earnings & Valuation

This table compares Schrödinger and BioMarin Pharmaceutical's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Schrödinger$85.54 million50.30$-24,570,000.00N/AN/A
BioMarin Pharmaceutical$1.70 billion8.29$-23,850,000.00$0.071,104.86

BioMarin Pharmaceutical has higher revenue and earnings than Schrödinger.

Summary

BioMarin Pharmaceutical beats Schrödinger on 9 of the 11 factors compared between the two stocks.

Schrödinger (NASDAQ:SDGR) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, earnings, dividends, analyst recommendations and institutional ownership.

Analyst Ratings

This is a breakdown of current recommendations for Schrödinger and Grifols, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Schrödinger01302.75
Grifols03502.63

Schrödinger presently has a consensus target price of $84.00, indicating a potential upside of 36.70%. Given Schrödinger's stronger consensus rating and higher probable upside, analysts clearly believe Schrödinger is more favorable than Grifols.

Insider and Institutional Ownership

41.3% of Schrödinger shares are held by institutional investors. Comparatively, 15.2% of Grifols shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Schrödinger and Grifols' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Schrödinger-19.92%-7.25%-5.33%
Grifols12.79%10.65%4.79%

Earnings & Valuation

This table compares Schrödinger and Grifols' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Schrödinger$85.54 million50.30$-24,570,000.00N/AN/A
Grifols$5.71 billion2.25$700.16 million$1.1715.97

Grifols has higher revenue and earnings than Schrödinger.

Summary

Grifols beats Schrödinger on 6 of the 10 factors compared between the two stocks.

Schrödinger (NASDAQ:SDGR) and Dr. Reddy's Laboratories (NYSE:RDY) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, earnings, dividends, analyst recommendations and institutional ownership.

Analyst Ratings

This is a breakdown of current recommendations for Schrödinger and Dr. Reddy's Laboratories, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Schrödinger01302.75
Dr. Reddy's Laboratories00303.00

Schrödinger presently has a consensus target price of $84.00, indicating a potential upside of 36.70%. Dr. Reddy's Laboratories has a consensus target price of $70.00, indicating a potential downside of 2.78%. Given Schrödinger's higher probable upside, analysts clearly believe Schrödinger is more favorable than Dr. Reddy's Laboratories.

Insider and Institutional Ownership

41.3% of Schrödinger shares are held by institutional investors. Comparatively, 12.9% of Dr. Reddy's Laboratories shares are held by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Schrödinger and Dr. Reddy's Laboratories' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Schrödinger-19.92%-7.25%-5.33%
Dr. Reddy's Laboratories8.23%16.33%10.79%

Earnings & Valuation

This table compares Schrödinger and Dr. Reddy's Laboratories' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Schrödinger$85.54 million50.30$-24,570,000.00N/AN/A
Dr. Reddy's Laboratories$2.32 billion5.17$259 million$2.7925.81

Dr. Reddy's Laboratories has higher revenue and earnings than Schrödinger.

Summary

Dr. Reddy's Laboratories beats Schrödinger on 7 of the 10 factors compared between the two stocks.


Schrödinger Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Elanco Animal Health logo
ELAN
Elanco Animal Health
1.9$35.01+0.6%$16.56 billion$3.07 billion-61.42Analyst Report
Analyst Revision
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.6$135.89+0.1%$15.97 billion$219.75 million-17.36Insider Selling
Zai Lab logo
ZLAB
Zai Lab
1.6$153.99+0.7%$14.58 billion$12.98 million-50.82Earnings Announcement
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
2.1$77.34+0.5%$14.13 billion$1.70 billion17.70
Grifols logo
GRFS
Grifols
1.3$18.69+0.3%$12.85 billion$5.71 billion16.69News Coverage
Dr. Reddy's Laboratories logo
RDY
Dr. Reddy's Laboratories
1.3$72.00+0.0%$11.97 billion$2.32 billion59.50Earnings Announcement
Analyst Report
Teva Pharmaceutical Industries logo
TEVA
Teva Pharmaceutical Industries
1.4$10.76+1.8%$11.75 billion$16.89 billion-2.92
Bausch Health Companies logo
BHC
Bausch Health Companies
1.9$29.25+0.6%$10.48 billion$8.60 billion-5.37
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
1.9$176.80+1.3%$10.06 billion$2.16 billion55.77Analyst Report
Maravai LifeSciences logo
MRVI
Maravai LifeSciences
1.5$38.40+1.2%$9.89 billionN/A0.00Earnings Announcement
Analyst Report
Lockup Expiration
Analyst Revision
United Therapeutics logo
UTHR
United Therapeutics
1.7$198.29+0.2%$8.88 billion$1.45 billion18.76
BridgeBio Pharma logo
BBIO
BridgeBio Pharma
2.0$54.13+0.9%$8.08 billion$40.56 million-15.87
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.6$155.50+0.7%$8.00 billion$3.34 million-20.19Analyst Upgrade
Analyst Revision
News Coverage
Gap Down
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.3$73.05+0.3%$7.60 billion$87.99 million-86.96
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.7$110.29+0.5%$7.44 billion$103.71 million-25.12
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.5$135.63+2.5%$7.29 billion$14.98 million-16.52Upcoming Earnings
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.3$218.96+0.0%$6.86 billion$311.33 million-127.30
Perrigo logo
PRGO
Perrigo
2.2$45.46+0.9%$6.07 billion$4.84 billion-757.54Earnings Announcement
Analyst Revision
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$75.13+1.2%$5.99 billion$380.83 million-9.61
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$93.88+2.7%$5.48 billion$66.51 million17.32Insider Selling
Allakos logo
ALLK
Allakos
1.7$100.54+0.1%$5.39 billionN/A-36.69Analyst Downgrade
Analyst Revision
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$37.32+2.5%$5.26 billion$1.12 billion77.75Analyst Report
Galapagos logo
GLPG
Galapagos
1.3$77.00+1.1%$5.04 billion$1.00 billion-11.67Analyst Report
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$33.85+1.2%$4.79 billion$150,000.00-15.97Earnings Announcement
Analyst Revision
I-Mab logo
IMAB
I-Mab
1.2$63.60+2.0%$4.60 billion$4.31 million-2.20News Coverage
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$70.27+0.6%$4.57 billionN/A-5.73Analyst Report
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$53.06+16.6%$4.27 billionN/A-7.15Analyst Report
High Trading Volume
Unusual Options Activity
News Coverage
Gap Up
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$72.75+2.6%$4.25 billion$6.87 million-7.03
LEGN
Legend Biotech
1.3$30.90+4.2%$4.11 billion$64.39 million0.00Analyst Report
High Trading Volume
News Coverage
Gap Up
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$26.75+3.5%$3.98 billion$204.89 million-33.44
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$60.89+0.9%$3.70 billion$806.43 million-8.62
Alkermes logo
ALKS
Alkermes
1.2$22.08+0.8%$3.54 billion$1.17 billion-48.00
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$70.45+1.6%$3.46 billionN/A-20.07
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.5$55.72+0.9%$3.43 billion$117.91 million-11.30
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$21.23+2.5%$3.40 billion$339.08 million-12.34Analyst Revision
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$18.19+4.3%$3.32 billion$114.62 million-7.33Analyst Report
Insider Selling
Arvinas logo
ARVN
Arvinas
1.7$67.24+0.5%$3.29 billion$42.98 million-26.27
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$110.73+2.8%$3.26 billionN/A-55.09
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.2$60.29+2.8%$3.23 billion$1.11 billion19.39
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$37.10+1.3%$3.01 billion$60,000.00-11.52Analyst Upgrade
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$79.07+0.9%$2.86 billion$26.52 million-6.97
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$73.29+0.9%$2.80 billion$644.77 million-10.46Upcoming Earnings
MorphoSys logo
MOR
MorphoSys
0.3$20.93+0.1%$2.75 billion$80.43 million99.67
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.3$61.60+1.0%$2.71 billion$421.03 million21.69Analyst Report
Insmed logo
INSM
Insmed
1.2$26.04+0.7%$2.69 billion$136.47 million-10.02Analyst Report
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.5$38.00+0.0%$2.68 billion$306.98 million-5.44Analyst Report
News Coverage
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$40.40+1.3%$2.56 billionN/A-22.20Earnings Announcement
Analyst Revision
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.7$21.41+0.8%$2.50 billion$306.49 million24.06
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$49.42+1.9%$2.47 billion$963.01 million15.35Analyst Report
News Coverage
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.4$9.23+2.8%$2.46 billion$182.24 million-8.03Analyst Revision
This page was last updated on 5/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.